Cardiovascular Systems develops, manufactures, and markets devices for the treatment of vascular diseases, targeting a range of plaque types in leg arteries above and below the knee. The company was founded in 1989 and is based in St. Paul, Minnesota.
CSII Price Forecast Based on DCF Valuation
DCF Fair Value Target:
Below please find a table outlining a discounted cash flow forecast for CSII, in which we model out valuation assuming a variety of terminal growth rates. To summarize, we found that Cardiovascular Systems Inc ranked in the 0th percentile in terms of potential gain offered. We should note, though, that all scenearios modelled for this stock suggest it is overvalued. In terms of the factors that were most noteworthy in this DCF analysis for CSII, they are:
The company's compound free cash flow growth rate over the past 3.26 years comes in at -0.38%; that's greater than only 3.37% of US stocks we're applying DCF forecasting to.
The company has produced more trailing twelve month cash flow than only 4.92% of its sector Healthcare.
The business' balance sheet suggests that 2% of the company's capital is sourced from debt; this is greater than only 6.85% of the free cash flow producing stocks we're observing.
Terminal Growth Rate in Free Cash Flow
Return Relative to Current Share Price
AGHC, ALC, ANGO, ELAN, and HAPP can be thought of as valuation peers to CSII, in the sense that they are in the Healthcare sector and have a similar price forecast based on DCF valuation.